Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

ONZETRA XSAIL

SUMATRIPTAN SUCCINATE

Standard Dose
EQ 11MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ONZETRA XSAIL is listed in Drugs@FDA under application 206099 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN SUCCINATE Form and strength POWDER;NASAL - EQ 11MG BASE Sponsor CURRAX Submission history Latest submission status date: 2019-12-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview ONZETRA XSAIL is listed in Drugs@FDA under application 206099 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN SUCCINATE Form and strength POWDER;NASAL - EQ 11MG BASE Sponsor CURRAX Submission history Latest submission status date: 2019-12-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.